tetano
Editor, Senior Moderator
J Drug Target. 2016 Mar 9:1-34. [Epub ahead of print]
[h=1]Microneedle delivery of trivalent influenza vaccine to the skin induces long-term cross-protection.[/h] Kim YC[SUP]1[/SUP], Lee SH[SUP]2[/SUP], Choi WH[SUP]3[/SUP], Choi HJ[SUP]4[/SUP], Goo TW[SUP]5[/SUP], Lee JH[SUP]6[/SUP], Quan FS[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] A painless self-immunization method with effective and broad cross-protection is urgently needed to prevent infections against newly emerging influenza viruses. In this study, we investigated the cross-protection efficacy of trivalent influenza vaccine containing inactivated A/PR/8/34 (H1N1), A/Hong Kong/68 (H3N2), and B/Lee/40 after skin vaccination using microneedle patches coated with this vaccine. Microneedle vaccination of mice in the skin provided 100% protection against lethal challenges with heterologous pandemic strain influenza A/California/04/09, heterogeneous A/Philippines/2/82, and B/Victoria/287 viruses 8 months after boost immunization. Cross-reactive serum IgG antibody responses against heterologous influenza viruses A/California/04/09, A/Philippines/2/82, and B/Victoria/287 were induced at high levels. Hemagglutination inhibition titers were also maintained at high levels against these heterogeneous viruses. Microneedle vaccination induced substantial levels of cross-reactive IgG antibody responses in the lung and cellular immune responses, as well as cross-reactive antibody-secreting plasma cells in the spleen. Viral loads in the lung were significantly (p < 0.05) reduced. All mice survived after viral challenges. These results indicate that skin vaccination with trivalent vaccine using a microneedle array could provide protection against seasonal epidemic or new pandemic strain of influenza viruses.
[h=4]KEYWORDS:[/h] influenza; microneedle; protection; trivalent vaccine
PMID: 26957023 [PubMed - as supplied by publisher]
[h=1]Microneedle delivery of trivalent influenza vaccine to the skin induces long-term cross-protection.[/h] Kim YC[SUP]1[/SUP], Lee SH[SUP]2[/SUP], Choi WH[SUP]3[/SUP], Choi HJ[SUP]4[/SUP], Goo TW[SUP]5[/SUP], Lee JH[SUP]6[/SUP], Quan FS[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] A painless self-immunization method with effective and broad cross-protection is urgently needed to prevent infections against newly emerging influenza viruses. In this study, we investigated the cross-protection efficacy of trivalent influenza vaccine containing inactivated A/PR/8/34 (H1N1), A/Hong Kong/68 (H3N2), and B/Lee/40 after skin vaccination using microneedle patches coated with this vaccine. Microneedle vaccination of mice in the skin provided 100% protection against lethal challenges with heterologous pandemic strain influenza A/California/04/09, heterogeneous A/Philippines/2/82, and B/Victoria/287 viruses 8 months after boost immunization. Cross-reactive serum IgG antibody responses against heterologous influenza viruses A/California/04/09, A/Philippines/2/82, and B/Victoria/287 were induced at high levels. Hemagglutination inhibition titers were also maintained at high levels against these heterogeneous viruses. Microneedle vaccination induced substantial levels of cross-reactive IgG antibody responses in the lung and cellular immune responses, as well as cross-reactive antibody-secreting plasma cells in the spleen. Viral loads in the lung were significantly (p < 0.05) reduced. All mice survived after viral challenges. These results indicate that skin vaccination with trivalent vaccine using a microneedle array could provide protection against seasonal epidemic or new pandemic strain of influenza viruses.
[h=4]KEYWORDS:[/h] influenza; microneedle; protection; trivalent vaccine
PMID: 26957023 [PubMed - as supplied by publisher]